Power Play

Biotech battles – a new front in US-China contest

Beyond chips, biotechnology is another area of concern, given its wide-ranging applications from drugs to food and fuel and supply chain vulnerabilities.

China has earmarked biotech as a priority industry for development in its “Made in China 2025” industrial master plan. PHOTO: AFP
Gift this subscriber-only story to your friends and family

WASHINGTON - The successful development of two mRNA vaccines against Covid-19, at the lightning-fast speed of barely a year, was hailed by analysts as a triumph for America’s biotechnology industry, and a sign that the superpower continued to lead the world in the sector.

In contrast, China’s Sinovac jabs, which use more traditional vaccine technology, have been shown to be less effective in preventing severe illness and require more doses for a similar level of protection.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.